Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

-Anticoagulant drugs-

D C Gulba1

  • 1Franz-Volhard-Klinik am Max-Delbrück-Zentrum für Molekulare Medizin, Klinikum Rudolf Virchow, Humboldt-Universität zu Berlin.

Herz
|February 1, 1996
PubMed
Summary
This summary is machine-generated.

Heparin and coumadin derivatives are vital anticoagulants for thrombo-embolic diseases. While heparin is safer for pregnancy, both carry bleeding risks, and coumadin has significant teratogenic effects, necessitating careful monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2017
Same author

[Triple therapy for patients with stent and atrial fibrillation? Yes!].

Deutsche medizinische Wochenschrift (1946)·2013
Same author

[Coronary artery disease--relevance of total coronary revascularization on the incidence of malignant arrhythmias].

Herzschrittmachertherapie & Elektrophysiologie·2007
Same author

[Postoperative antithrombotic treatment in diabetic patients].

Clinical research in cardiology : official journal of the German Cardiac Society·2006
Same author

Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms.

Atherosclerosis·2001
Same author

Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.

Journal of thrombosis and thrombolysis·2001
Same journal

[Advancing cardiovascular prevention : Evidence-based design of healthy and sustainable food environments].

Herz·2026
Same journal

[Effects of air pollution on cardiovascular health].

Herz·2026
Same journal

[Heart and climate].

Herz·2026
Same journal

Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.

Herz·2026
Same journal

[Noise and the heart].

Herz·2026
Same journal

[The cardiovascular exposome: areas of action for prevention and practical cardiology].

Herz·2026
See all related articles

Area of Science:

  • Pharmacology
  • Hematology
  • Internal Medicine

Background:

  • Anticoagulant drugs like heparin and coumadin derivatives are essential for treating thrombo-embolic diseases.
  • Heparin, a polysaccharide, is primarily used for short-term or bridging therapy due to poor oral bioavailability.
  • Coumadin derivatives are effective for long-term therapy due to enteral bioavailability but require strict monitoring.

Purpose of the Study:

  • To compare the efficacy and safety of heparin and coumadin derivatives in managing thrombo-embolic diseases.
  • To evaluate the suitability of these anticoagulants during pregnancy and lactation.
  • To highlight the adverse effects and monitoring requirements for both drug classes.

Main Methods:

  • Review of current medical literature on heparin and coumadin derivatives.

Related Experiment Videos

  • Analysis of clinical trial data regarding efficacy and safety profiles.
  • Comparison of pharmacokinetic and pharmacodynamic properties, including use in specific populations.

    • Main Results:

    • Fractionated heparins show improved subcutaneous absorption and reliable plasma levels, substituting for unfractionated heparin in certain conditions.
    • Heparin is considered safe during pregnancy and lactation, though it carries risks of bleeding and osteoporosis.
    • Coumadin derivatives are effective for long-term anticoagulation but are highly teratogenic and pose risks during pregnancy, requiring meticulous INR monitoring and management of drug interactions.

    Conclusions:

    • Both heparin and coumadin derivatives are critical for managing thrombo-embolic disorders, each with distinct advantages and disadvantages.
    • Heparin is preferred during pregnancy and lactation due to its safety profile, despite risks of bleeding and osteoporosis.
    • Coumadin therapy necessitates rigorous monitoring due to its narrow therapeutic index, drug interactions, and significant teratogenic potential, making it unsuitable for pregnant patients.